Treatment of Collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene

1. A method of upregulating a function of and/or the expression of a Collagen gene polynucleotide having SEQ ID NO: 3 in patient cells or tissues in vivo or in vitro comprising:

contacting said cells or tissues with at least one antisense oligonucleotide of 10-30 nucleotides in length that targets, is 100% complementary to and specifically hybridizes to a complementary region of a natural antisense oligonucleotide of the Collagen gene polynucleotide having SEQ ID NOS: 6, 7, 8 or 9 thereby upregulating a function of and/or the expression of the Collagen gene polynucleotide in patient cells or tissues in vivo or in vitro.

2. The method of claim 1 , wherein a function of and/or the expression of the Collagen gene is increased in vivo or in vitro with respect to a control.

3. The method of claim 1 , wherein the at least one antisense oligonucleotide targets a nucleic acid sequence comprising coding and/or non-coding nucleic acid sequences of a Collagen gene polynucleotide.

4. The method of claim 1 , wherein the at least one antisense oligonucleotide targets overlapping and/or non-overlapping sequences of a Collagen gene polynucleotide.

5. The method of claim 1 , wherein the at least one antisense oligonucleotide comprises one or more modifications selected from: at least one modified sugar moiety, at least one modified internucleoside linkage, at least one modified nucleotide, and combinations thereof.

6. The method of claim 5 , wherein the one or more modifications comprise at least one modified sugar moiety selected from: a 2′-O-methoxyethyl modified sugar moiety, a 2′-methoxy modified sugar moiety, a 2′-O-alkyl modified sugar moiety, a bicyclic sugar moiety, and combinations thereof.

7. The method of claim 5 , wherein the one or more modifications comprise at least one modified internucleoside linkage selected from: a phosphorothioate, alkylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, carboxymethyl ester, and combinations thereof.

8. The method of claim 5 , wherein the one or more modifications comprise at least one modified nucleotide selected from: a peptide nucleic acid (PNA), a locked nucleic acid (LNA), an arabino-nucleic acid (FANA), an analogue, a derivative, and combinations thereof.

9. The method of claim 1 , wherein the at least one oligonucleotide comprises at least one oligonucleotide sequence set forth as SEQ ID NOS: 20 to 28.

10. A method of treating a disease associated with the under expression of at least one Collagen gene polynucleotide and/or at least one encoded product thereof, comprising:

administering to a patient a therapeutically effective dose of at least one antisense oligonucleotide of 10 to 30 nucleotides in length that is 100 percent complementary to and binds to a natural antisense sequence of said at least one Collagen gene polynucleotide having SEQ ID NOS: 3 and upregulates expression of said at least one Collagen gene polynucleotide; thereby treating the disease associated with the at least one Collagen gene polynucleotide and/or at least one encoded product thereof.

11. The method of claim 10 , wherein a disease associated with the at least one Collagen gene polynucleotide is selected from: a collagen disorder, age related collagen degradation, Osteogenesis imperfecta, Otosclerosis (OTSC), Osteoporosis, Osteoarthritis, Oesophageal squamous cell cancer, chondrodysplasia, atypical Marfan syndrome, Ehlers-Danlos Syndrome (EDS), Dystrophic epidermolysis bullosa (DEB), Caffey disease, aneurysms (eg. intracranial aneurysms), idiopathic pulmonary fibrosis, liver cirrhosis, kidney fibrosis, liver fibrosis, heart fibrosis, scleroderma, hypertrophic scars, keloids, cancer, inflammation, a genetic disease (e.g. Duchenne muscular dystrophy), a neurological disease or disorder (e.g. Parkinson's, Alzheimer's, Huntington's, Gaucher disease), a metabolic disease (e.g. type I diabetes), an autoimmune disease or disorder, trauma (e.g. spinal cord injury, burns, etc), ischemia, and other blood vessel, heart, a skin disease or disorder, skin aging, a skin disease or disorder or condition requiring skin engineering, a liver or kidney disease requiring transplantation; tendon, bone or tissue regeneration; skeletal repair, cartilage and bone repair.

12. A method of treating a skin condition associated with the under expression of a Collagen gene polynucleotide having SEQ ID NO: 3 and/or at least one encoded product thereof, comprising:

administering to a patient having a skin condition or at risk of developing a skin condition a therapeutically effective dose of at least one antisense oligonucleotide of 10 to 30 nucleotides in length that is 100 percent complementary to and that binds to a natural antisense sequence of said at least one Collagen gene polynucleotide selected from the group consisting of SEQ ID NOS: 3 and upregulates expression of said at least one Collagen gene polynucleotide; thereby treating the disease skin condition associated with the at least one Collagen gene polynucleotide and/or at least one encoded product thereof.

13. The method of claim 12 , wherein the skin condition is caused by caused by inflammation, light damage or aging.

14. The method of claim 13 , wherein the skin condition is the development of wrinkles, contact dermatitis, atopic dermatitis, actinic keratosis, keratinization disorders, an epidermolysis bullosa disease, exfoliative dermatitis, seborrheic dermatitis, an erythema, discoid lupus erythematosus, dermatomyositis, skin cancer, or an effect of natural aging.